The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | The role of transplant in myeloma in 2021
Surbhi Sidana, MD, Stanford University, Stanford, CA, talks on the future role of transplant in multiple myeloma, highlighting data from the IFM2009 trial (NCT01191060) which showed that transplant achieved superior measurable residual disease (MRD)-negativity rates and progression-free survival, and data from the FORTE trial (NCT02203643), which demonstrated progression-free survival and sustained MRD-negativity in patients who receive upfront transplant. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
